Novartis patent expiration

1. Afinitor patent expiration

AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6004973 NOVARTIS Pharmaceutical compositions comprising rafamycin coprecipitates
Jul, 2016

(8 years ago)

US6004973

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising rafamycin coprecipitates
Jan, 2017

(7 years ago)

US5665772 NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Sep, 2019

(4 years ago)

US7741338 NOVARTIS Macrolides
Dec, 2019

(4 years ago)

US7297703 NOVARTIS Macrolides
Dec, 2019

(4 years ago)

US5665772

(Pediatric)

NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Mar, 2020

(4 years ago)

US7297703

(Pediatric)

NOVARTIS Macrolides
Jun, 2020

(4 years ago)

US8778962 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(2 years ago)

US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(2 years ago)

US8778962

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 10 months ago)

US8436010

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 10 months ago)

US8410131 NOVARTIS Cancer treatment
Nov, 2025

(1 year, 3 months from now)

US8410131

(Pediatric)

NOVARTIS Cancer treatment
May, 2026

(1 year, 9 months from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment
Jul, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-638) May 05, 2014
New Indication(I-650) Apr 26, 2015
New Indication(I-655) Jul 20, 2015
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE-11) May 05, 2018
Orphan Drug Exclusivity(ODE) Apr 26, 2019
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...

Dosage: TABLET

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

2. Alomide patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5457126 NOVARTIS Use of lodoxamide to treat ophthalmic allergic conditions
Oct, 2012

(11 years ago)




Drugs and Companies using LODOXAMIDE TROMETHAMINE ingredient

Market Authorisation Date: 23 September, 1993

Treatment: Treatment of ocular allergic response in human eyes

Dosage: SOLUTION/DROPS

More Information on Dosage

ALOMIDE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Amturnide patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5559111 NOVARTIS δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(5 years ago)

US8618174 NOVARTIS Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Nov, 2021

(2 years ago)

US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
May, 2023

(1 year, 2 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012
New Combination(NC) Dec 21, 2013

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 21 December, 2010

Treatment: Treatment of hypertension

Dosage: TABLET

More Information on Dosage

AMTURNIDE family patents

Family Patents

4. Arcapta Neohaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8658673 NOVARTIS BETA2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8796307 NOVARTIS Beta2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067437 NOVARTIS Beta-2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

5. Coartem patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5677331 NOVARTIS Antimalarial compositions
Oct, 2014

(9 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2014
Orphan Drug Exclusivity(ODE) Apr 07, 2016

Drugs and Companies using ARTEMETHER; LUMEFANTRINE ingredient

NCE-1 date: 07 April, 2013

Market Authorisation Date: 07 April, 2009

Treatment: Treatment of acute, uncomplicated malaria infection due to plasmodium falciparum in patients of 5kg bodyweight and above

Dosage: TABLET

More Information on Dosage

COARTEM family patents

Family Patents

6. Diovan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5399578

(Pediatric)

NOVARTIS Acyl compounds
Sep, 2012

(11 years ago)

US5972990 NOVARTIS Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Oct, 2016

(7 years ago)

US5972990

(Pediatric)

NOVARTIS Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Apr, 2017

(7 years ago)

US6294197 NOVARTIS Solid oral dosage forms of valsartan
Jun, 2017

(7 years ago)

US6294197

(Pediatric)

NOVARTIS Solid oral dosage forms of valsartan
Dec, 2017

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 19, 2024

Drugs and Companies using VALSARTAN ingredient

Market Authorisation Date: 14 August, 2002

Treatment: Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction; Treatment of hypertensi...

Dosage: TABLET

How can I launch a generic of DIOVAN before it's drug patent expiration?
More Information on Dosage

DIOVAN family patents

Family Patents

7. Diovan Hct patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5399578

(Pediatric)

NOVARTIS Acyl compounds
Sep, 2012

(11 years ago)

US6294197 NOVARTIS Solid oral dosage forms of valsartan
Jun, 2017

(7 years ago)

US6294197

(Pediatric)

NOVARTIS Solid oral dosage forms of valsartan
Dec, 2017

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-567) Jul 31, 2011

Drugs and Companies using HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 06 March, 1998

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of DIOVAN HCT before it's drug patent expiration?
More Information on Dosage

DIOVAN HCT family patents

Family Patents

8. Emadine patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5441958 NOVARTIS Ophthalmic compositions comprising emedastine and methods for their use
Dec, 2013

(10 years ago)




Drugs and Companies using EMEDASTINE DIFUMARATE ingredient

Market Authorisation Date: 29 December, 1997

Treatment: Treatment of allergic conjunctivitis

Dosage: SOLUTION/DROPS

More Information on Dosage

EMADINE family patents

Family Patents

9. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE's oppositions filed in EPO
ENTRESTO SPRINKLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877938 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS Methods of treatment and pharmaceutical composition
Jan, 2025

(5 months from now)

US9388134 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(2 years from now)

US10722471 NOVARTIS Galenic formulations of organic compounds
Feb, 2037

(12 years from now)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: Treatment of heart failure; Treatment of heart failure with oral pellets

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

10. Exelon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4948807 NOVARTIS Phenyl carbamates
Aug, 2012

(11 years ago)

US5602176 NOVARTIS Phenyl carbamate
Feb, 2014

(10 years ago)




Drugs and Companies using RIVASTIGMINE TARTRATE ingredient

Market Authorisation Date: 21 April, 2000

Treatment: Treatment of alzheimer's dementia

Dosage: CAPSULE; SOLUTION

How can I launch a generic of EXELON before it's drug patent expiration?
More Information on Dosage

EXELON family patents

Family Patents

11. Exforge patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5399578

(Pediatric)

NOVARTIS Acyl compounds
Sep, 2012

(11 years ago)

US6294197 NOVARTIS Solid oral dosage forms of valsartan
Jun, 2017

(7 years ago)

US6294197

(Pediatric)

NOVARTIS Solid oral dosage forms of valsartan
Dec, 2017

(6 years ago)

US6395728 NOVARTIS Method of treatment and pharmaceutical composition
Jul, 2019

(5 years ago)




Drugs and Companies using AMLODIPINE BESYLATE; VALSARTAN ingredient

Market Authorisation Date: 20 June, 2007

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EXFORGE before it's drug patent expiration?
More Information on Dosage

EXFORGE family patents

Family Patents

12. Exforge Hct patent expiration

EXFORGE HCT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5399578

(Pediatric)

NOVARTIS Acyl compounds
Sep, 2012

(11 years ago)

US6294197 NOVARTIS Solid oral dosage forms of valsartan
Jun, 2017

(7 years ago)

US6294197

(Pediatric)

NOVARTIS Solid oral dosage forms of valsartan
Dec, 2017

(6 years ago)

US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
May, 2023

(1 year, 2 months ago)

US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents
May, 2023

(1 year, 2 months ago)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
Nov, 2023

(8 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 30, 2012

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 30 April, 2009

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EXFORGE HCT before it's drug patent expiration?
More Information on Dosage

EXFORGE HCT family patents

Family Patents

13. Exjade patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6596750 NOVARTIS Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Jun, 2017

(7 years ago)

US6465504 NOVARTIS Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Nov 02, 2012
New Indication(I-665) Jan 23, 2016
Orphan Drug Exclusivity(ODE-39) Jan 23, 2020
M(M-239) Dec 12, 2021
M(M-241) Jul 24, 2022
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 02 November, 2005

Treatment: Method of treating chronic iron overload

Dosage: TABLET, FOR SUSPENSION

How can I launch a generic of EXJADE before it's drug patent expiration?
More Information on Dosage

EXJADE family patents

Family Patents

14. Fabhalta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9682968 NOVARTIS Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Jul, 2034

(9 years from now)

US11603363 NOVARTIS Crystalline form of LNP023
May, 2041

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951101 NOVARTIS Methods of using factor B inhibitors
Jul, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2028
Orphan Drug Exclusivity(ODE-456) Dec 05, 2030

Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient

NCE-1 date: 06 December, 2027

Market Authorisation Date: 05 December, 2023

Treatment: Treatment of paroxysmal nocturnal hemoglobinuria (pnh) by administration of 200 mg of iptacopan twice daily

Dosage: CAPSULE

More Information on Dosage

FABHALTA family patents

Family Patents

15. Famvir patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866581 NOVARTIS Penciclovir for the treatment of post therapeutic neuralgia
Oct, 2014

(9 years ago)

US6124304 NOVARTIS Penciclovir for the treatment of zoster associated pain
Oct, 2014

(9 years ago)

US5866581

(Pediatric)

NOVARTIS Penciclovir for the treatment of post therapeutic neuralgia
Apr, 2015

(9 years ago)

US6124304

(Pediatric)

NOVARTIS Penciclovir for the treatment of zoster associated pain
Apr, 2015

(9 years ago)

US5916893 NOVARTIS Treatment of a latent infection of herpes virus
Sep, 2015

(8 years ago)

US5840763 NOVARTIS Treatment of a latent infection of herpes viruses
Sep, 2015

(8 years ago)

US5916893

(Pediatric)

NOVARTIS Treatment of a latent infection of herpes virus
Mar, 2016

(8 years ago)

US5840763

(Pediatric)

NOVARTIS Treatment of a latent infection of herpes viruses
Mar, 2016

(8 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-54) Dec 24, 2012
Pediatric Exclusivity(PED) Jun 24, 2013
M(M-98) Jan 31, 2014
M(M-112) Feb 09, 2015

Drugs and Companies using FAMCICLOVIR ingredient

Market Authorisation Date: 11 December, 1995

Treatment: Method of treating varicella zoster (shingles) infections

Dosage: TABLET

How can I launch a generic of FAMVIR before it's drug patent expiration?
More Information on Dosage

FAMVIR family patents

Family Patents

16. Foradil patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488027 NOVARTIS Powder inhaler
Mar, 2019

(5 years ago)

US6887459 NOVARTIS Aerosol composition comprising formoterol
Nov, 2020

(3 years ago)




Drugs and Companies using FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 16 February, 2001

Treatment: Treatment of chronic obstructive pulmonary disease

Dosage: POWDER

More Information on Dosage

FORADIL family patents

Family Patents

17. Gilenya patent expiration

GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5604229 NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Feb, 2019

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5604229 NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Feb, 2014

(10 years ago)

US6004565 NOVARTIS Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
Sep, 2017

(6 years ago)

US5604229

(Pediatric)

NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Aug, 2019

(4 years ago)

US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Mar, 2026

(1 year, 8 months from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Sep, 2026

(2 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(2 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(3 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(3 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(7 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-106) Jul 20, 2014
New Chemical Entity Exclusivity(NCE) Sep 21, 2015
New Strength(NS) May 11, 2021
New Patient Population(NPP) May 11, 2021
Pediatric Exclusivity(PED) Nov 11, 2021

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

NCE-1 date: 11 November, 2020

Market Authorisation Date: 11 May, 2018

Treatment: Treatment of autoimmune disease; Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating...

Dosage: CAPSULE

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents

18. Gleevec patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43932 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5521184 NOVARTIS Pyrimidine derivatives and processes for the preparation thereof
Jan, 2015

(9 years ago)

US5521184

(Pediatric)

NOVARTIS Pyrimidine derivatives and processes for the preparation thereof
Jul, 2015

(9 years ago)

USRE43932 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jan, 2019

(5 years ago)

US7544799 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jan, 2019

(5 years ago)

US6894051 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
May, 2019

(5 years ago)

USRE43932

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2019

(5 years ago)

US7544799

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2019

(5 years ago)

US6894051

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Nov, 2019

(4 years ago)

US6958335 NOVARTIS Treatment of gastrointestinal stromal tumors
Dec, 2021

(2 years ago)

US6958335

(Pediatric)

NOVARTIS Treatment of gastrointestinal stromal tumors
Jun, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-583) Dec 19, 2011
Orphan Drug Exclusivity(ODE) Jan 25, 2020
New Indication(I-666) Jan 25, 2016
Orphan Drug Exclusivity(ODE-40) Jan 25, 2020

Drugs and Companies using IMATINIB MESYLATE ingredient

Market Authorisation Date: 18 April, 2003

Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)

Dosage: TABLET; CAPSULE

How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage

GLEEVEC family patents

Family Patents

19. Izba patent expiration

IZBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Mar, 2029

(4 years from now)

US8754123 NOVARTIS Pharmaceutical compositions having desirable bioavailability
May, 2029

(4 years from now)

US8178582 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(5 years from now)

US8722735 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 15, 2017

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS

How can I launch a generic of IZBA before it's drug patent expiration?
More Information on Dosage

IZBA family patents

Family Patents

20. Jadenu Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6465504 NOVARTIS Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-239) Dec 12, 2021
M(M-241) Jul 24, 2022
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 18 May, 2017

Treatment: NA

Dosage: GRANULE

More Information on Dosage

JADENU SPRINKLE family patents

Family Patents

21. Kisqali patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(3 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(5 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(6 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(5 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(5 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-784) Jul 18, 2021
New Indication(I-783) Jul 18, 2021
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-n...

Dosage: TABLET

How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage

KISQALI family patents

Family Patents

22. Kisqali Femara Co-pack (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(3 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(5 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(6 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(5 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(5 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(7 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...

Dosage: TABLET

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

Family Patents

23. Leqvio patent expiration

LEQVIO's oppositions filed in EPO
LEQVIO IPR and PTAB Proceedings
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(2 years ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(2 years ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(1 year, 4 months ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(8 months ago)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(6 months ago)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(4 months ago)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(2 months ago)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(2 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10590418 NOVARTIS Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Jul, 2022

(2 years ago)

US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(8 months ago)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(3 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION

More Information on Dosage

LEQVIO family patents

Family Patents

24. Locametz patent expiration

LOCAMETZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11369590 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer

Dosage: POWDER

More Information on Dosage

LOCAMETZ family patents

Family Patents

25. Mayzent patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(6 years from now)

US11944602 NOVARTIS Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Jul, 2036

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 26, 2024
M(M-274) Mar 01, 2025

Drugs and Companies using SIPONIMOD ingredient

NCE-1 date: 27 March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically ...

Dosage: TABLET

How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage

MAYZENT family patents

Family Patents

26. Mekinist patent expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(2 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(10 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 4 months from now)

US7378423

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Nov, 2027

(3 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(6 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9399021

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9155706

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US8580304

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE-48) May 29, 2020
Orphan Drug Exclusivity(ODE) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Dec 22, 2025
New Indication(I-908) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfacto...

Dosage: TABLET; SOLUTION

More Information on Dosage

MEKINIST family patents

Family Patents

27. Myfortic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6172107 NOVARTIS Entric-coated pharmaceutical compositions
Apr, 2017

(7 years ago)

US6025391 NOVARTIS Enteric-coated pharmaceutical compositions of mycophenolate
Apr, 2017

(7 years ago)

US6306900 NOVARTIS Enteric coated pharmaceutical compositions
Feb, 2018

(6 years ago)




Drugs and Companies using MYCOPHENOLIC SODIUM ingredient

Market Authorisation Date: 27 February, 2004

Treatment: Prophylaxis of organ rejection in patients receiving allogeneic renal transplants

Dosage: TABLET, DELAYED RELEASE

How can I launch a generic of MYFORTIC before it's drug patent expiration?
More Information on Dosage

MYFORTIC family patents

Family Patents

28. Neoral patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5985321 NOVARTIS Soft gelatin capsule manufacture
Sep, 2014

(9 years ago)




Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 July, 1995

Treatment: NA

Dosage: SOLUTION; CAPSULE

More Information on Dosage

NEORAL family patents

Family Patents

29. Patanase patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399508 NOVARTIS Olopatadine formulations for topical nasal administration
Sep, 2022

(1 year, 10 months ago)

US7977376 NOVARTIS Olopatadine formulations for topical nasal administration
Feb, 2023

(1 year, 5 months ago)

US8399508

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration
Mar, 2023

(1 year, 4 months ago)

US7977376

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration
Aug, 2023

(11 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 01, 2012
Pediatric Exclusivity(PED) Jun 01, 2013

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2008

Treatment: Allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of PATANASE before it's drug patent expiration?
More Information on Dosage

PATANASE family patents

Family Patents

30. Piqray patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(5 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
New Indication(I-937) Jan 18, 2027

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET

More Information on Dosage

PIQRAY family patents

Family Patents

31. Pluvicto patent expiration

PLUVICTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11318121 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10406240 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10398791 NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 23 March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...

Dosage: SOLUTION

More Information on Dosage

PLUVICTO family patents

Family Patents

32. Promacta patent expiration

PROMACTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6280959 NOVARTIS Metal complexes
Oct, 2018

(5 years ago)

US6280959

(Pediatric)

NOVARTIS Metal complexes
Apr, 2019

(5 years ago)

US7473686 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7332481 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7790704 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7452874 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7332481

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7452874

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7473686

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7790704

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(1 year, 7 months ago)

US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(1 year, 1 month ago)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(1 year, 1 month ago)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(7 months ago)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jan, 2026

(1 year, 5 months from now)

US8062665 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8052993 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8828430 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8071129 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8052994 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8052995 NOVARTIS 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(3 years from now)

US8071129

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)

US8052994

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)

US8828430

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)

US8052993

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)

US8062665

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)

US8052995

(Pediatric)

NOVARTIS 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Indication(I-664) Nov 16, 2015
Orphan Drug Exclusivity(ODE) Nov 20, 2015
New Indication(I-711) Jun 11, 2018
New Dosing Schedule(D-149) Jun 11, 2018
Orphan Drug Exclusivity(ODE-75) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
Orphan Drug Exclusivity(ODE-210) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

NCE-1 date: 26 February, 2021

Market Authorisation Date: 20 October, 2011

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of idiopathic thrombocytopenic purpura (itp); Treatmen...

Dosage: TABLET

How can I launch a generic of PROMACTA before it's drug patent expiration?
More Information on Dosage

PROMACTA family patents

Family Patents

33. Promacta Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6280959 NOVARTIS Metal complexes
Oct, 2018

(5 years ago)

US7452874 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7473686 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(1 year, 7 months ago)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6280959

(Pediatric)

NOVARTIS Metal complexes
Apr, 2019

(5 years ago)

US7790704 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7332481 NOVARTIS Thrombopoietin mimetics
May, 2021

(3 years ago)

US7452874

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7332481

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7473686

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7790704

(Pediatric)

NOVARTIS Thrombopoietin mimetics
Nov, 2021

(2 years ago)

US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(1 year, 1 month ago)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(1 year, 1 month ago)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(7 months ago)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jan, 2026

(1 year, 5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE-74) Aug 26, 2021
Orphan Drug Exclusivity(ODE) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
ODE*(ODE*) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 27 September, 2018

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 ...

Dosage: FOR SUSPENSION

How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage

PROMACTA KIT family patents

Family Patents

34. Rydapt patent expiration

RYDAPT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(1 year, 8 months ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(4 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
Orphan Drug Exclusivity(ODE-140) Apr 28, 2024
Orphan Drug Exclusivity(ODE-141) Apr 28, 2024
Orphan Drug Exclusivity(ODE) Apr 28, 2024

Drugs and Companies using MIDOSTAURIN ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...

Dosage: CAPSULE

How can I launch a generic of RYDAPT before it's drug patent expiration?
More Information on Dosage

RYDAPT family patents

Family Patents

35. Sandostatin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5753618 NOVARTIS Somatostatin analogue composition and use in treating breast cancer
May, 2015

(9 years ago)

US5753618

(Pediatric)

NOVARTIS Somatostatin analogue composition and use in treating breast cancer
Nov, 2015

(8 years ago)




Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 21 October, 1988

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of SANDOSTATIN before it's drug patent expiration?
More Information on Dosage

SANDOSTATIN family patents

Family Patents

36. Sandostatin Lar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5538739 NOVARTIS Sustained release formulations of water soluble peptides
Jul, 2013

(10 years ago)

US5538739

(Pediatric)

NOVARTIS Sustained release formulations of water soluble peptides
Jan, 2014

(10 years ago)

US5639480 NOVARTIS Sustained release formulations of water soluble peptides
Jun, 2014

(10 years ago)

US5688530 NOVARTIS Sustained release formulations of water soluble peptides
Nov, 2014

(9 years ago)

US5639480

(Pediatric)

NOVARTIS Sustained release formulations of water soluble peptides
Dec, 2014

(9 years ago)

US5688530

(Pediatric)

NOVARTIS Sustained release formulations of water soluble peptides
May, 2015

(9 years ago)

US5922682 NOVARTIS Polyol esters, their preparation and use in depot forms of pharmacologically active agents
Jul, 2016

(8 years ago)

US5922338 NOVARTIS Polyol esters, their preparation and use in depot forms of pharmacologically active agents
Jul, 2016

(8 years ago)

US5922682

(Pediatric)

NOVARTIS Polyol esters, their preparation and use in depot forms of pharmacologically active agents
Jan, 2017

(7 years ago)

US5922338

(Pediatric)

NOVARTIS Polyol esters, their preparation and use in depot forms of pharmacologically active agents
Jan, 2017

(7 years ago)




Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 25 November, 1998

Treatment: Acromegaly

Dosage: INJECTABLE

More Information on Dosage

SANDOSTATIN LAR family patents

Family Patents

37. Scemblix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(8 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2026
Orphan Drug Exclusivity(ODE-381) Oct 29, 2028
Orphan Drug Exclusivity(ODE-382) Oct 29, 2028
ODE*(ODE*) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 29 October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: TABLET

More Information on Dosage

SCEMBLIX family patents

Family Patents

38. Seebri patent expiration

SEEBRI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6521260 NOVARTIS Carrier particles for use in dry powder inhalers
Jan, 2016

(8 years ago)

US6582678 NOVARTIS Carrier particles for use in dry powder inhalers
Apr, 2018

(6 years ago)

US6528678 NOVARTIS Phosgene-free process for preparing carbamates
Apr, 2018

(6 years ago)

US8029768 NOVARTIS Treatment of respiratory diseases
Apr, 2021

(3 years ago)

US7229607 NOVARTIS Treatment of respiratory disease
Apr, 2021

(3 years ago)

US7736670 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US9962338 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US9931304 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8435567 NOVARTIS Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Jun, 2021

(3 years ago)

US8048451 NOVARTIS Pharmaceutical compositions for inhalation
Jun, 2021

(3 years ago)

US8303991 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8580306 NOVARTIS Particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8956661 NOVARTIS Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof
Jun, 2021

(3 years ago)

US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 29, 2018

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER

More Information on Dosage

SEEBRI family patents

Family Patents

39. Starlix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5463116 NOVARTIS Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
Oct, 2012

(11 years ago)

US5488150 NOVARTIS Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them
Jan, 2013

(11 years ago)

US6844008 NOVARTIS Tablet composition
Nov, 2017

(6 years ago)

US6641841 NOVARTIS Tablet composition
Nov, 2017

(6 years ago)

US6559188 NOVARTIS Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
Sep, 2020

(3 years ago)

US6878749 NOVARTIS Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
Sep, 2020

(3 years ago)




Drugs and Companies using NATEGLINIDE ingredient

Market Authorisation Date: 22 December, 2000

Treatment: Use as a blood glucose-lowering agent; Use for treatment of diabetes, particularly type 2 diabetes

Dosage: TABLET

How can I launch a generic of STARLIX before it's drug patent expiration?
More Information on Dosage

STARLIX family patents

Family Patents

40. Tafinlar patent expiration

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(10 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 4 months from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
May, 2029

(4 years from now)

US9233956

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Nov, 2029

(5 years from now)

US8415345

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US7994185

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(6 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)

US11504333 NOVARTIS Pharmaceutical composition
Jun, 2038

(13 years from now)

US11504333

(Pediatric)

NOVARTIS Pharmaceutical composition
Dec, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 16, 2026
Pediatric Exclusivity(PED) Sep 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...

Dosage: TABLET, FOR SUSPENSION; CAPSULE

More Information on Dosage

TAFINLAR family patents

Family Patents

41. Tasigna patent expiration

TASIGNA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(1 year, 15 days ago)

US8415363 NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(1 year, 11 months from now)

US8163904 NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Aug, 2028

(4 years from now)

US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(1 year, 15 days ago)

US7169791

(Pediatric)

NOVARTIS Inhibitors of tyrosine kinases
Jan, 2024

(6 months ago)

US8389537 NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(1 year, 11 months from now)

US8501760 NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jul, 2026

(1 year, 11 months from now)

US8501760

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jan, 2027

(2 years from now)

US8389537

(Pediatric)

NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(2 years from now)

US8415363

(Pediatric)

NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(2 years from now)

US8293756 NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Sep, 2027

(3 years from now)

US8293756

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Mar, 2028

(3 years from now)

US8163904

(Pediatric)

NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Feb, 2029

(4 years from now)

US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Oct, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2012
New Indication(I-627) Jun 17, 2014
Orphan Drug Exclusivity(ODE) Oct 29, 2014
New Dosing Schedule(D-170) Dec 22, 2020
New Patient Population(NPP) Mar 22, 2021
Orphan Drug Exclusivity(ODE-171) Mar 22, 2025
Orphan Drug Exclusivity(ODE-172) Mar 22, 2025
Orphan Drug Exclusivity(ODE-380) Sep 23, 2028
Pediatric Exclusivity(PED) Mar 23, 2029

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 23 March, 2028

Market Authorisation Date: 22 March, 2018

Treatment: A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...

Dosage: CAPSULE

How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage

TASIGNA family patents

Family Patents

42. Tekamlo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5559111 NOVARTIS δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(5 years ago)

US8613949 NOVARTIS Galenical formulations of organic compounds
Dec, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012
New Combination(NC) Aug 26, 2013

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 26 August, 2010

Treatment: Treatment of hypertension

Dosage: TABLET

More Information on Dosage

TEKAMLO family patents

Family Patents

43. Trileptal patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7037525 NOVARTIS Oxacarbazepine film-coated tablets
Feb, 2018

(6 years ago)

US7037525

(Pediatric)

NOVARTIS Oxacarbazepine film-coated tablets
Aug, 2018

(5 years ago)

US8119148 NOVARTIS Suspension comprising oxcarbazepine
Dec, 2020

(3 years ago)

US8119148

(Pediatric)

NOVARTIS Suspension comprising oxcarbazepine
Jun, 2021

(3 years ago)




Drugs and Companies using OXCARBAZEPINE ingredient

Market Authorisation Date: 14 January, 2000

Treatment: Method of treating seizures

Dosage: TABLET; SUSPENSION

How can I launch a generic of TRILEPTAL before it's drug patent expiration?
More Information on Dosage

TRILEPTAL family patents

Family Patents

44. Tykerb patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513262 NOVARTIS Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Jan, 2019

(5 years ago)

US8821927 NOVARTIS Pharmaceutical composition
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6391874 NOVARTIS Fused heterocyclic compounds as protein tyrosine kinase inhibitors
Jul, 2017

(7 years ago)

US6828320 NOVARTIS Heterocyclic compounds
Jul, 2017

(7 years ago)

US6727256 NOVARTIS Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Jan, 2019

(5 years ago)

US6713485 NOVARTIS Heterocyclic compounds
Sep, 2020

(3 years ago)

US7157466 NOVARTIS Quinazoline ditosylate salt compounds
Nov, 2021

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 13, 2012
New Indication(I-620) Jan 29, 2013
M(M-235) Dec 06, 2021

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

NCE-1 date: 14 March, 2011

Market Authorisation Date: 13 March, 2007

Treatment: Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including anthracycline, a taxane and trastuzumab

Dosage: TABLET

How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage

TYKERB family patents

Family Patents

45. Tyzeka patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795238 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6566344 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6444652 NOVARTIS β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6395716 NOVARTIS β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Aug, 2019

(4 years ago)

US6569837 NOVARTIS β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
Oct, 2020

(3 years ago)

US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(10 months ago)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(10 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2011
M(M-124) Jan 28, 2016

Drugs and Companies using TELBIVUDINE ingredient

NCE-1 date: 25 October, 2010

Market Authorisation Date: 25 October, 2006

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: TABLET; SOLUTION

More Information on Dosage

TYZEKA family patents

Family Patents

46. Utibron patent expiration

UTIBRON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6521260 NOVARTIS Carrier particles for use in dry powder inhalers
Jan, 2016

(8 years ago)

US6582678 NOVARTIS Carrier particles for use in dry powder inhalers
Apr, 2018

(6 years ago)

US8283362 NOVARTIS Beta-2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8067437 NOVARTIS Beta-2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8796307 NOVARTIS Beta2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8658673 NOVARTIS BETA2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US7820694 NOVARTIS Beta-2-adrenoreceptor agonists
Jun, 2020

(4 years ago)

US8029768 NOVARTIS Treatment of respiratory diseases
Apr, 2021

(3 years ago)

US7229607 NOVARTIS Treatment of respiratory disease
Apr, 2021

(3 years ago)

US8303991 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US9962338 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8956661 NOVARTIS Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof
Jun, 2021

(3 years ago)

US9931304 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8048451 NOVARTIS Pharmaceutical compositions for inhalation
Jun, 2021

(3 years ago)

US8435567 NOVARTIS Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Jun, 2021

(3 years ago)

US8580306 NOVARTIS Particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US7736670 NOVARTIS Method of making particles for use in a pharmaceutical composition
Jun, 2021

(3 years ago)

US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Product(NP) Oct 29, 2018

Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER

More Information on Dosage

UTIBRON family patents

Family Patents

47. Valturna patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5559111 NOVARTIS δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(5 years ago)

US8168616 NOVARTIS Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
Jul, 2026

(1 year, 11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012
New Combination(NC) Sep 16, 2012

Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 16 September, 2009

Treatment: Treatment of hypertension

Dosage: TABLET

More Information on Dosage

VALTURNA family patents

Family Patents

48. Vijoice patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(5 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
Orphan Drug Exclusivity(ODE-396) Apr 05, 2029

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 05 April, 2022

Treatment: NA

Dosage: TABLET

More Information on Dosage

VIJOICE family patents

Family Patents

49. Vitravene Preservative Free patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5442049 NOVARTIS Oligonucleotides for modulating the effects of cytomegalovirus infections
Aug, 2012

(11 years ago)

US5595978 NOVARTIS Composition and method for treatment of CMV retinites
Aug, 2012

(11 years ago)




Drugs and Companies using FOMIVIRSEN SODIUM ingredient

Market Authorisation Date: 26 August, 1998

Treatment: Treatment of cmv retinitis by intravitreal admin of a phosphorothioate oligonucleotide capable of hybridizing with cmv mrna

Dosage: INJECTABLE

More Information on Dosage

VITRAVENE PRESERVATIVE FREE family patents

Family Patents

50. Votrient patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7262203 NOVARTIS Pyrimidineamines as angiogenesis modulators
Dec, 2021

(2 years ago)

US8114885 NOVARTIS Chemical compounds
Dec, 2021

(2 years ago)

US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(8 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 19, 2014
New Indication(I-649) Apr 26, 2015
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Orphan Drug Exclusivity(ODE-23) Apr 26, 2019

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

NCE-1 date: 19 October, 2013

Market Authorisation Date: 19 October, 2009

Treatment: NA

Dosage: TABLET

More Information on Dosage

VOTRIENT family patents

Family Patents

51. Zometa patent expiration

ZOMETA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4939130 NOVARTIS Substituted alkanediphosphonic acids and pharmaceutical use
Sep, 2012

(11 years ago)

US4939130

(Pediatric)

NOVARTIS Substituted alkanediphosphonic acids and pharmaceutical use
Mar, 2013

(11 years ago)

US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(10 months from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(1 year, 4 months from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Sep 20, 2011

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 20 August, 2001

Treatment: Hypercalcemia of malignancy

Dosage: INJECTABLE

How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage

ZOMETA family patents

Family Patents

52. Zortress patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6440990 NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Sep, 2013

(10 years ago)

US6440990

(Pediatric)

NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Mar, 2014

(10 years ago)

US6004973 NOVARTIS Pharmaceutical compositions comprising rafamycin coprecipitates
Jul, 2016

(8 years ago)

US6004973

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising rafamycin coprecipitates
Jan, 2017

(7 years ago)

US6455518 NOVARTIS Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Jul, 2017

(6 years ago)

US6239124 NOVARTIS Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Aug, 2017

(6 years ago)

US6455518

(Pediatric)

NOVARTIS Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Jan, 2018

(6 years ago)

US6239124

(Pediatric)

NOVARTIS Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Feb, 2018

(6 years ago)

US5665772 NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Sep, 2019

(4 years ago)

US5665772

(Pediatric)

NOVARTIS O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Mar, 2020

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 20, 2013
Pediatric Exclusivity(PED) Sep 30, 2014
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-668) Feb 15, 2016

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 30 September, 2013

Market Authorisation Date: 20 April, 2010

Treatment: Prophylaxis of allograft rejection in adult patients receiving a liver transplant; Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant

Dosage: TABLET

How can I launch a generic of ZORTRESS before it's drug patent expiration?
More Information on Dosage

ZORTRESS family patents

Family Patents

53. Zykadia patent expiration

ZYKADIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7153964 NOVARTIS Pyrimidine compounds
Feb, 2021

(3 years ago)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 5 months ago)

US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 5 months ago)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 5 months ago)

US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 5 months ago)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(1 year, 9 months from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(3 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(3 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(5 years from now)

US8039474 NOVARTIS 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
Jun, 2030

(5 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(3 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors
Feb, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2019
ODE*(ODE*) May 26, 2024

Drugs and Companies using CERITINIB ingredient

NCE-1 date: 29 April, 2018

Market Authorisation Date: 18 March, 2019

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: CAPSULE

More Information on Dosage

ZYKADIA family patents

Family Patents